September 21, 2024 by European College of Neuropsychopharmacology Credit: CC0 Public DomainA direct comparison between the experimental psychedelic drug psilocybin and a standard SSRI antidepressant shows similar improvement of depressive symptoms, but that psilocybin offers additional longer-term benefits. The comparison, between psilocybin (the active ingredient in “magic mushrooms”) and the SSRI escitalopram gave similar long-term...
By Paul McClure July 24, 2023 A clinical trial has found that psilocybin therapy may be an effective treatment for anorexia nervosa Depositphotos A new phase 1 clinical trial has found that a single dose of psilocybin combined with psychotherapy may be a promising treatment for anorexia nervosa, a mental illness that is notoriously difficult...
by Cactus Communications Effect of psilocybin on percentage of freezing time in an auditory cued FC and fear extinction paradigm. (A) The auditory cued FC and fear extinction paradigm and the experimental plan. (B) FC significantly prolonged the percentage of freezing time of mice in context A (fear conditioning context). (C) On the day of...
PARIS — A single 25-mg dose of a synthetic formulation of psilocybin appears to improve the core symptoms of treatment-resistant depression (TRD), a new analysis of phase 2 trial data suggests. Known as COMP360, the synthetic agent, a proprietary, purified form of psilocybin, improved symptoms related to mood and anhedonia while leaving aspects such as...
by Bob Yirka, Medical Xpress Credit: Pixabay/CC0 Public Domain A combined team of researchers from University Roma Tre and Nova Mentis Life Science Corp. has found that administering microdoses of psilocybin to rats with fragile X syndrome (FXS), an autism-like disease, improves some aspects of cognitive performance. In their paper published in the journal Psychopharmacology, the...
Lolita Osorio April 11, 2022 Dr Robin Carhart-Harris New research points to a general mechanism that may explain how psychedelics act on the brain to alleviate depression and potentially other psychiatric conditions marked by fixed patterns of thinking, including rumination and excessive self-focus. Led by investigators from the University of California San Francisco and Imperial...
KING’S COLLEGE LONDON New research from the Institute of Psychiatry, Psychology, & Neuroscience (IoPPN) at King’s College London, in partnership with COMPASS Pathways, has established that psilocybin can be safely administered at doses of either 10mg or 25mg to up to six participants simultaneously. The research, published in The Journal of Psychopharmacology, is an essential...
by Central Institute of Mental Health (CIMH) Alcohol dependence: Psilocybin reduces relapsesFig. 1. Alcohol-induced infralimbic mGluR2 deficit leads to impaired ASST performance.(A) Scheme of chronic alcohol-vapor exposure leading to stable blood alcohol concentrations and significantly increased somatic withdrawal scores. After 3 weeks of abstinence, batches of animals were used either for spine density analysis, attentional...
By Rich Haridy; November 22, 2020 An exploratory trial found a single dose of psilocybin cut migraine frequency by half in the two weeks following taking the drug A first-of-its-kind exploratory study, led by researchers from Yale School of Medicine, has found a single dose of the psychedelic psilocybin can reduce migraine frequency by 50 percent for...
by Johns Hopkins University School of Medicine In a small study of adults with major depression, Johns Hopkins Medicine researchers report that two doses of the psychedelic substance psilocybin, given with supportive psychotherapy, produced rapid and large reductions in depressive symptoms, with most participants showing improvement and half of study participants achieving remission through the four-week follow-up. A...
